Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapeutics targeting obesity, metabolic, and liver diseases. Its lead product, pemvidutide, is a dual GLP-1/glucagon receptor agonist designed to promote weight loss, reduce liver fat, and improve metabolic health. Altimmune focuses on innovative treatments addressing comorbidities of obesity and metabolic-associated steatohepatitis (MASH), leveraging proprietary technology and clinical development to serve patients with unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.